ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Therefore, this review provides a comprehensive overview of our current understanding of NTRK-mediated tumorigenesis in hematological malignancies and links recent successes in NTRK-targeted therapy to historical milestones achieved by the targeting of BCR–ABL1 in CML.